Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has shared an announcement.
Wai Chun Bio-Technology Limited has called an extraordinary general meeting in Hong Kong on 20 April 2026 for shareholders to vote on approving, confirming and ratifying a loan agreement, its related drawdowns and the associated transactions. The notice details procedural arrangements for proxy voting, share registration closure and contingency plans for severe weather on the meeting date, underscoring the importance of securing formal shareholder approval for the company’s financing arrangements.
The meeting will determine whether the proposed loan framework receives shareholder backing, which could influence Wai Chun Bio-Technology’s capital structure and financial flexibility. Shareholders are instructed on how to qualify to vote, submit proxies and navigate potential adjournments, indicating that the company is taking structured steps to ensure due process and regulatory compliance around this key funding decision.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange, operating in the bio-technology sector. The company maintains its head office and principal place of business in Hong Kong, where it is overseen by a board led by Chairman and CEO Lam Ka Chun alongside three independent non-executive directors.
Average Trading Volume: 151,902
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.51M
Learn more about 0660 stock on TipRanks’ Stock Analysis page.